Matsukiyococokara & Co. · TSE:3088

Matsukiyococokara & — Q1 FY2026 Earnings Presentation

16 slides from Matsukiyococokara &'s earnings presentation, Aug 10, 2026

  1. Slide 1: Financial Results for the Three Months Ended June 30, 2026

    This document is a translation of the original Japanese document for reference purposes only. In the event of any discrepancy between this document and the Japanese original, the original shall prevail. Financial Results for the Three Months Ended June 30, 2026 Copyright 2026 August 10, 2026 Matsuki

  2. Slide 2: Table of contents

    Table of contents Financial Results for 1Q FY2026 Financial Summary (YoY) ・・・・・・ 2 Segment Results (YoY) ・・・・・・ 3 Segment Results (YoY) ) (Reference) ・・・・・・ 4 Excluding amortization of goodwill and trademark rights of cocokara fine Inc. and Shinseidoyakkyoku co. ltd. Net Sales by Product ・・・・・・ 5 Ba

  3. Slide 3: Financial Summary (YoY)

    Financial Results for 1Q FY2026 Financial Summary (YoY) ◼ Both sales and profit reached record highs for the the first quarter exceeding the plan. ◼ Sales increased, driven by strategic growth in cosmetics. Profit increased as gross profit margin improved due to strengthening of pharmaceuticals and

  4. Slide 4: Segment Results (YoY)

    Financial Results for 1Q FY2026 Segment Results (YoY) ◼ In the Matsumotokiyoshi Group business, sales and profit increased due to the strong performance of cosmetics— driven by expanding beauty flagship stores and strengthening product assortment—as well as new store openings in urban areas. ◼ Cocok

  5. Slide 5: Segment Results (YoY) (Reference)

    Financial Results for 1Q FY2026 Segment Results (YoY) ◼ Excluding amortization of goodwill and trademark rights of cocokara fine Inc. totaling ¥1.809 billion Reference ◼ Excluding amortization of goodwill and trademark rights of Shinseidoyakkyoku co., ltd. totaling ¥86 million (Millions of yen) Mats

  6. Slide 6: Net Sales by Product

    Financial Results for 1Q FY2026 Net Sales by Product ◼ The Health and Beauty category composition ratio increased to 72.7% due to successful enhancements to product assortment and stores. ◼ Gross profit margin improved due to the steady promotion of priority measures and strengthened sales of PB pro

  7. Slide 7: Balance Sheet

    Financial Results for 1Q FY2026 Balance Sheet ◼ Total assets decreased by approximately ¥18.8 billion from the end of the previous fiscal year due to the acquisition of treasury shares and dividend payments. ◼ Liabilities: Approx. ¥12.2 billion decrease due to tax payments. ◼ Equity ratio: 73.2%. (+

  8. Slide 8: Store Openings, Closings, and Renovations in Japan

    Financial Results for 1Q FY2026 Store Openings, Closings, and Renovations in Japan ◼ We are making steady progress with store openings in urban areas and renovations, including the expansion of beauty flagship stores. ◼ As of April 1, 2026, UNIVERSAL DRUG CO.,LTD. became a subsidiary. (Unit: No. of

  9. Slide 9: Assumptions for FY2026 Financial Forecasts

    Financial Forecasts for FY2026 Assumptions for FY2026 Financial Forecasts １．Assumptions Same-Store Sales Growth Full Year +0.7％（1H +0.7％、2H +0.6％） Openings 130（MKG 100、CFG 30） Closings 60（MKG 20、CFG 40） Renovations 80（MKG 50、CFG 30） AppBrew Inc. , UNIVERSAL DRUG CO.,LTD. Newly consolidated （Shinseid

  10. Slide 10: FY2026 Financial Forecasts (Quarterly)

    Financial Forecasts for FY2026 FY2026 Financial Forecasts（Quarterly） ◼ There are no revisions to the consolidated earnings forecast announced on May 13, 2026 Full Year 1H 2H 1Q 2Q 3Q 4Q YoY YoY YoY YoY YoY YoY YoY （Millions of yen/%） (%/pt) (%/pt) (%/pt) (%/pt) (%/pt) (%/pt) (%/pt) Net sales 1,155,0

  11. Slide 11: Stores by Area in Japan

    【Appendix】 Stores by Area in Japan Group total 3,650 Stores in Japan (As of Jun. 30, 2026) ❚ Matsumotokiyoshi Group Business（MKG） ：1,992 ❚ Cocokarafine Group Business（CFG） ：1,527 Hokkaido Tohoku 128 ❚ And Company Business （ACP） ：131 MKG 94 CFG 34 Overseas 105 Koshinetsu ❚ Taiwan 24 Thailand 37 Vietn

  12. Slide 12: Customer Contact Points, and PB Product Sales

    【Appendix】 Customer Contact Points, and PB Product Sales PB product sales Customer contact points Sales composition ratio of PB products 14.7 ％ 2,629 SKU Total 172 millon （ １QYoY +0.7pt ） （As of Jun. 30, 2026） （As of Jun. 30, 2026） "SPICA," a beauty item for diet support that enhances beauty while p

  13. Slide 13: Quarterly Consolidated Financial Results

    【Appendix】 Quarterly Consolidated Financial Results FY2025 FY2026 1Q 2Q 1H 3Q 4Q Full Year 1Q 2Q 1H 3Q 4Q Full Year （Millions of yen/%） Net sales 273,643 275,451 549,094 290,246 278,099 1,117,440 289,348 Gross profit 94,283 97,276 191,559 102,275 99,949 393,784 103,375 Gross profit 34.5 35.3 34.9 35

  14. Slide 14: Quarterly Segment Results

    【Appendix】 Quarterly Segment Results FY2024 FY2025 （Millions of yen/％） 1Q 2Q 1H 3Q 4Q Full Year 1Q 2Q 1H 3Q 4Q Full Year Matsumoto- Sales 175,393 176,430 351,823 182,941 176,648 711,413 183,891 kiyoshi Segment Group 14,339 13,854 28,194 16,541 16,082 60,818 16,100 profit Business Segment profit marg

  15. Slide 15: Quarterly Net Sales and Gross Profit by Product

    【Appendix】 Quarterly Net Sales and Gross Profit by Product FY2025 FY2026 (Millions of yen/％) 1Q 2Q 1H 3Q 4Q Full Year 1Q 2Q 1H 3Q 4Q Full Year Sales 91,887 93,125 185,012 102,182 100,511 387,707 98,150 Medical and Segment pharmaceutic al products profit 38,728 42,186 80,915 44,960 45,461 171,337 42,

  16. Slide 16: Cautionary Statement

    Cautionary Statement This document contains future outlooks such as plans, forecasts, strategies, and others which are not historical fact and these are made by the management’s judgement based on the obtainable information at the time of the disclosure. Actual results may significantly differ from

MatsukiyoCocokara & — Q1 FY2026 Earnings Presentation on 6ix